| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | KRAS, KRAS1, KRAS2, K-Ras 2, K RAS2A, K RAS2B, K RAS4A, K RAS4B, Ki-Ras, c-Ki-ras, c-K-ras, cK Ras, cK-ras, RASK2, RASK_HUMAN, NS3, NS, p21ras, K RAS p21 protein, GTPase KRas, Transforming protein p21, Oncogene KRAS2, Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog, v Ki ras2 Kirsten rat sarcoma viral oncogene homolog, Cellular c Ki ras2 proto oncogene, PR310 cK ras oncogene, KIRSTEN MURINE SARCOMA VIRUS 2 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | Synthetic peptide from the C-terminal of Human KRAS (aa. 100-189) |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
KRAS, a well-characterized oncogene encoding a small GTPase, is emerging as a critical player in neurodegenerative disease research. Traditionally studied in cancer biology, KRAS regulates key cellular processes such as proliferation, differentiation, and survival through the MAPK/ERK and PI3K/AKT pathways. Recent studies suggest that dysregulation of KRAS signaling may contribute to neuronal vulnerability, synaptic dysfunction, and neuroinflammation—hallmarks of disorders like Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
In the central nervous system, KRAS is expressed in neurons and glial cells, where it modulates neurodevelopmental signaling and cellular stress responses. Aberrant KRAS activity has been linked to impaired autophagy, mitochondrial dysfunction, and altered neurotrophic signaling, all of which are implicated in progressive neurodegeneration. Moreover, KRAS-mediated pathways intersect with tau phosphorylation and amyloid precursor protein processing, positioning KRAS as a potential upstream regulator of pathogenic cascades.
Understanding KRAS function in neural contexts opens new avenues for therapeutic intervention. Targeting KRAS or its downstream effectors may offer neuroprotective strategies, particularly in early-stage disease. As neuroscience increasingly intersects with molecular oncology, KRAS represents a promising biomarker and mechanistic bridge between cancer biology and neurodegeneration.
Cite this product varies by variant:
- SPC-777D — Size: 100 ug: KRAS Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D, RRID: AB_2728995)
- SPC-777D-A390 — Size: 100 ug: KRAS Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-A390, RRID: AB_2731602)
- SPC-777D-A488 — Size: 100 ug: KRAS Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-A488, RRID: AB_2731603)
- SPC-777D-A594 — Size: 100 ug: KRAS Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-A594, RRID: AB_2731605)
- SPC-777D-APC — Size: 100 ug: KRAS Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-APC, RRID: AB_2731611)
- SPC-777D-BI — Size: 100 ug: KRAS Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-BI, RRID: AB_2731612)
- SPC-777D-FITC — Size: 100 ug: KRAS Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-FITC, RRID: AB_2731613)
- SPC-777D-HRP — Size: 100 ug: KRAS Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-HRP, RRID: AB_2731614)
- SPC-777D-PCP — Size: 100 ug: KRAS Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-PCP, RRID: AB_2731616)
- SPC-777D-RPE — Size: 100 ug: KRAS Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777D-RPE, RRID: AB_2731617)
- SPC-777S — Size: 12 ug: KRAS Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-777S, RRID: AB_2728995)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.